

Rev. Inst. Med. Trop. Sao Paulo
54(4):237-238, July-August, 2012
doi: 10.1590/S0036-46652012000400013

LETTER TO THE EDITOR

UNIVERSAL VARICELLA VACCINATION NEEDS TO BE HIGH ON THE AGENDA IN CHINA

Shanghai, June 3rd, 2012

Dear Editor,

Varicella is highly contagious, with a clinical attack rate of 60%-90% following household exposure of susceptible individuals⁴. It was not a notifiable infectious disease in China, national data on incidence rate and statistics concerning hospitalizations and deaths attributable to varicella were not available until 2005. Since then, varicella has been required to be reported to the National Notifiable Diseases Reporting System (NNDRS). According to the data from NNDRS, the incidence of varicella in China is increasing annually. Thus, it is estimated that the national average incidence of varicella was 12.0, 20.6, 23.8, 24.1 and 24.3 per 100,000 inhabitants from 2006 to 2010 respectively^{11,12}. However such incidence rates may be underestimated, the actual incidence rates should be much higher. A recent study of epidemiological data on varicella in Shanghai Zhabei district between 2005 and 2006 revealed that more than half of the outbreak cases were not reported to NNDRS³. The main reason for this is that the rate of missing reports on varicella from the medical institutions is extremely high³. Therefore, the varicella monitoring and reporting system in China needs to be improved.

Before introduction of the varicella vaccine, there were about four million cases of varicella annually in the United States, with an average of 11,000-13,500 hospitalizations and 100-150 deaths^{2,7}. After implementation of the varicella vaccination program in 1995, varicella age-specific incidence rates significantly declined for all age groups⁶. During 1995-2005, in two US varicella active surveillance sites where high vaccine coverage was achieved in young children, the incidence of varicella among children aged 0-14 years declined by 90% and that among adults aged ≥ 20 years declined by 74%⁶. In addition, varicella-related hospitalizations and deaths decreased substantially⁷. It has been demonstrated that one dose of varicella vaccine was 84.5% effective (median; mean 80.7%) in preventing all varicella and 100% effective (median and mean) in preventing severe varicella⁹.

Besides the United States, varicella vaccine has been licensed for the universal vaccination of children in a number of developed countries¹. Furthermore, it has been expanding in Latin American countries, for example Brazil and Uruguay⁸. Nonetheless, varicella vaccination of children aged ≥ 12 months has not been incorporated into the national or provincial childhood immunization schedules in China. A major obstacle is the high cost of this vaccine, which is 10 times more expensive than rubella vaccine and 75 times more expensive than measles vaccine in China⁵. Statistics showed that only 26.9% children ≤ 12 years of age in Shanghai received varicella vaccine during 1999-2005¹⁰.

In addition to having positive effects on disease prevention and control, mathematical models indicate that routine childhood vaccination against varicella may provide economic benefits for the individual and society¹. A recent study suggested that the universal varicella vaccination program was worthwhile in China and the benefit-cost ratio of one dose of routine varicella vaccine was 4.19¹³. Assessment of the epidemiology of varicella and evidence for the effectiveness of varicella vaccination provide support for the routine childhood vaccination in China. Therefore, in our own opinion, China should make a decision on the implementation of the universal varicella vaccination program.

Yi ZHANG (1,2)
Guo-Qing ZANG (1)
Zheng-Hao TANG (1)
Yong-Sheng YU (1)

(1) Department of Infectious Diseases, Shanghai Sixth People's Hospital,
Shanghai Jiao Tong University, Shanghai, P. R. China
(2) Medical College of Soochow University, Suzhou, P. R. China

Correspondence to: Yong-Sheng Yu,
Department of Infectious Diseases, Shanghai Sixth People's Hospital,
Shanghai Jiao Tong University, 600 Yishan Road, 200233 Shanghai, P. R. China
Phone: + 86 21 64369181-58673. Fax: + 86 21 24058384
E-mail: yuyongsheng@medmail.com.cn

REFERENCES

1. Bonanni P, Breuer J, Gershon A, Gershon M, Hryniewicz W, Papaevangelou V, *et al.* Varicella vaccination in Europe - taking the practical approach. *BMC Med.* 2009;7:26.
2. Hambleton S, Gershon AA. Preventing varicella-zoster disease. *Clin Microbiol Rev.* 2005;18:70-80.
3. Huang J, Xu MG. Analysis on varicella epidemiology in Zhabei district from 2005-2006 (Chinese). *Xian Dai Yu Fang Yi Xue.* (Modern Preventive Medicine). 2010;37:2001-3,2006.
4. Lee BR, Feaver SL, Miller CA, Hedberg CW, Ehresmann KR. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. *J Infect Dis.* 2004;190:477-83.
5. Ma H, Fontaine R. Varicella outbreak among primary school students--Beijing, China, 2004. *MMWR Morb Mortal Wkly Rep.* 2006;55:39-43.
6. Marin M, Watson TL, Chaves SS, Civen R, Watson BM, Zhang JX, *et al.* Varicella among adults: data from an active surveillance project, 1995-2005. *J Infect Dis.* 2008;197(Suppl 2):S94-100.
7. Reynolds MA, Watson BM, Plott-Adams KK, Jumaan AO, Galil K, Maupin TJ, *et al.* Epidemiology of varicella hospitalizations in the United States, 1995-2005. *J Infect Dis.* 2008;197(Suppl 2):S120-6.
8. Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Suga S, Yoshikawa T, *et al.* Varicella vaccination in Japan, South Korea, and Europe. *J Infect Dis.* 2008;197(Suppl 2):S185-90.
9. Seward JF, Marin M, Vázquez M. Varicella vaccine effectiveness in the US vaccination program: a review. *J Infect Dis.* 2008;197(Suppl 2):S82-9.
10. Wu HY, Zhang AX, Ren H, Li YT. An epidemiological investigation on varicella vaccination among children in some areas of Shanghai (Chinese). *Shanghai Yu Fang Yi Xue Za Zhi.* (Shanghai Journal of Preventive Medicine). 2006;18:437-9.
11. Yan L, Yin HM, Huang G, Shen JY, Niu JJ, Wang SW. Geographical epidemiology study on chickenpox features in China (Chinese). *Zhongguo Er Tong Bao Jian Za Zhi.* (Chinese Journal of Child Health Care). 2011;19:518-23.
12. Yin DP. Descriptively analysis of varicella of China in 2006 (Chinese). *Yu Fang Yi Xue Lun Tan.* (Preventive Medicine Tribune). 2007;13:488-9.
13. Yin DP, Luo LY, Song LZ, Zhang XS, Li FJ, Guo QY, *et al.* Initial economic evaluation of immunization of freeze-dried varicella attenuated live vaccine in China (Chinese). *Zhongguo Yi Miao He Mian Yi.* Chinese Journal of Vaccines and Immunization. 2011;17:1-4.